<?xml version="1.0" encoding="UTF-8"?>
<!--generator='jetpack-16.4-a.3'-->
<!--Jetpack_Sitemap_Buffer_News_XMLWriter-->
<?xml-stylesheet type="text/xsl" href="//bitacorafarmaceutica.com/news-sitemap.xsl"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd">
 <url>
  <loc>https://bitacorafarmaceutica.com/paises/latinoamerica/sudamerica/brasil/brasil-receta-electronica-sncr-octubre-2026/</loc>
  <lastmod>2026-10-26T12:33:17Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Latin Pharma News</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Brasil: qué revisar en una receta electrónica después del 30 de octubre</news:title>
   <news:publication_date>2026-10-26T11:16:59Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://bitacorafarmaceutica.com/mercado/sarampion-americas-vacunas-abastecimiento-2026/</loc>
  <lastmod>2026-10-26T11:52:36Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Latin Pharma News</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Sarampión: comprar vacunas exige saber quién sigue sin protección</news:title>
   <news:publication_date>2026-10-26T11:06:18Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://bitacorafarmaceutica.com/paises/latinoamerica/sudamerica/brasil/vivaxin-malaria-vivax-vacuna-brasil-fase-1-2026/</loc>
  <lastmod>2026-10-26T11:53:50Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Latin Pharma News</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Vivaxin: la investigación brasileña aborda una malaria con otra biología</news:title>
   <news:publication_date>2026-10-26T11:02:55Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://bitacorafarmaceutica.com/paises/latinoamerica/centroamerica-caribe/costa-rica/gutis-planta-costa-rica-expansion-internacional-2026/</loc>
  <lastmod>2026-10-26T12:33:28Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Latin Pharma News</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Gutis abre una nueva etapa industrial y debe construir su siguiente mercado</news:title>
   <news:publication_date>2026-10-26T10:59:40Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://bitacorafarmaceutica.com/paises/latinoamerica/wait-2026-acceso-innovacion-fifarma-iqvia-latinoamerica/</loc>
  <lastmod>2026-10-26T12:33:40Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Latin Pharma News</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>W.A.I.T. 2026: qué decisiones se esconden detrás de los 68 meses</news:title>
   <news:publication_date>2026-10-26T10:54:08Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://bitacorafarmaceutica.com/negocios/merck-kgaa-silence-sirna-divesiran-2026/</loc>
  <lastmod>2026-10-26T11:52:10Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Latin Pharma News</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Merck–Silence: comprar una plataforma con una apuesta clínica central</news:title>
   <news:publication_date>2026-10-26T10:50:48Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://bitacorafarmaceutica.com/tecnologia/pathos-bms-tempus-ia-datos-ensayos-neurologicos-2026/</loc>
  <lastmod>2026-10-26T11:54:04Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Latin Pharma News</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Pathos, BMS y Tempus: el contrato permite examinar la promesa de IA</news:title>
   <news:publication_date>2026-10-26T10:42:06Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://bitacorafarmaceutica.com/paises/lab-big-pharma/estados-unidos/fda-apps-medicamentos-software-guia-final-2026/</loc>
  <lastmod>2026-10-26T11:53:01Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Latin Pharma News</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>La FDA lleva el contenido de las apps al examen del medicamento</news:title>
   <news:publication_date>2026-10-26T10:33:32Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://bitacorafarmaceutica.com/negocios/roche-hansoh-adc-licensing-oncologia-2026/</loc>
  <lastmod>2026-10-26T12:34:04Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Latin Pharma News</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Roche y Hansoh: el valor detrás de una nueva apuesta por los ADC</news:title>
   <news:publication_date>2026-10-25T06:19:13Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
</urlset>
